Background: Patients with ischemic stroke (IS) or TIA face an elevated cardiovascular risk, warranting intensive lipid-lowering therapy. Despite recommendations, adherence to guidelines is suboptimal, leading to frequent undertreatment. This study aims to evaluate the statin use after IS and TIA. Methods: LIPYDS is a multicenter, observational, retrospective study including ≥ 18-year-old patients discharged after IS/TIA from 19 Italian centers in 2021. Multivariable logistic regression analysis was used to determine (1) the association between statin prescription (Any-statin versus No-statin), type (High-Intensity-statin versus Other-statin [Moderate/Low-Intensity]) with stroke etiology (TOAST), (2) clinical variables independently associated with statin prescription in the entire cohort and within TOAST categories. Results: We included 3,740 patients (median age 75 [IQR 64–82]; median LDL-C 104 [IQR 79–131]). At discharge, 1,971 (52.7%) received a High-intensity-statin, 800 (21.4%) Other-statin, 969 (25.9%) No-statin therapy. Among patients not on statin therapy before the event (N = 2686 [71.8%]), 50.1% initiated High-intensity-statin (78.2% of those with Large-Artery-Atherosclerosis, 60.8% Small-Vessel-Disease, 34.7% Cardioembolic, 47.4% Undetermined etiology); in 33% the decision to abstain from initiating statin therapy persisted. Large-Artery-Atherosclerosis showed the strongest association with Any-statin (aOR 3.07 [95%CI 2.39−3.95], p < 0.001) and High-intensity-statin (aOR 4.51 [95%CI 3.39−6.00], p < 0.001), while Cardioembolic stroke showed an inverse association (respectively, aOR 0.36 [95%CI 0.31−0.43], p < 0.001 and aOR 0.52 [95%CI 0.44−0.62], p < 0.001). Stepwise regression highlighted LDL-C and previous statin therapy as consistent predictors of statin at discharge. Older patients and women were less likely to be on a high-intensity formulation. Conclusion: Statins, especially at high-intensity, are under-prescribed after IS and TIA, with older patients, women and those with non-atherosclerotic strokes being the most affected.
Patterns and predictors of statin therapy after ischemic stroke and TIA: insights from the LIPYDS multicenter study / Cascio Rizzo, A.; Schwarz, G.; Paolucci, M.; Cavallini, A.; Mazzacane, F.; Candelaresi, P.; De Mase, A.; Marcheselli, S.; Straffi, L.; Poretto, V.; Giometto, B.; Diomedi, M.; Bagnato, M. R.; Zedde, M.; Grisendi, I.; Petruzzellis, M.; Galotto, D.; Morotti, A.; Padovani, A.; Bonaffini, N.; Cupini, L. M.; Caso, V.; Bossi, F.; Fanciulli, C.; Viola, M. M.; Persico, A.; Spina, E.; Falcou, A.; Pantoni, L.; Mele, F.; Silvestrini, M.; Viticchi, G.; Pilato, F.; Cappellari, M.; Anticoli, S.; La Spina, P.; Sessa, M.; Toni, D.; Zini, A.; Agostoni, E. C.. - In: NEUROLOGICAL SCIENCES. - ISSN 1590-1874. - 46:5(2025), pp. 2183-2194. [10.1007/s10072-024-07969-9]
Patterns and predictors of statin therapy after ischemic stroke and TIA: insights from the LIPYDS multicenter study
Giometto B.;
2025-01-01
Abstract
Background: Patients with ischemic stroke (IS) or TIA face an elevated cardiovascular risk, warranting intensive lipid-lowering therapy. Despite recommendations, adherence to guidelines is suboptimal, leading to frequent undertreatment. This study aims to evaluate the statin use after IS and TIA. Methods: LIPYDS is a multicenter, observational, retrospective study including ≥ 18-year-old patients discharged after IS/TIA from 19 Italian centers in 2021. Multivariable logistic regression analysis was used to determine (1) the association between statin prescription (Any-statin versus No-statin), type (High-Intensity-statin versus Other-statin [Moderate/Low-Intensity]) with stroke etiology (TOAST), (2) clinical variables independently associated with statin prescription in the entire cohort and within TOAST categories. Results: We included 3,740 patients (median age 75 [IQR 64–82]; median LDL-C 104 [IQR 79–131]). At discharge, 1,971 (52.7%) received a High-intensity-statin, 800 (21.4%) Other-statin, 969 (25.9%) No-statin therapy. Among patients not on statin therapy before the event (N = 2686 [71.8%]), 50.1% initiated High-intensity-statin (78.2% of those with Large-Artery-Atherosclerosis, 60.8% Small-Vessel-Disease, 34.7% Cardioembolic, 47.4% Undetermined etiology); in 33% the decision to abstain from initiating statin therapy persisted. Large-Artery-Atherosclerosis showed the strongest association with Any-statin (aOR 3.07 [95%CI 2.39−3.95], p < 0.001) and High-intensity-statin (aOR 4.51 [95%CI 3.39−6.00], p < 0.001), while Cardioembolic stroke showed an inverse association (respectively, aOR 0.36 [95%CI 0.31−0.43], p < 0.001 and aOR 0.52 [95%CI 0.44−0.62], p < 0.001). Stepwise regression highlighted LDL-C and previous statin therapy as consistent predictors of statin at discharge. Older patients and women were less likely to be on a high-intensity formulation. Conclusion: Statins, especially at high-intensity, are under-prescribed after IS and TIA, with older patients, women and those with non-atherosclerotic strokes being the most affected.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione
